Last checked at 19 Mar 2019 07:00
NetScientific plc
("NetScientific" or the "Company")
PDS merger with Edge Therapeutics update
Further to its announcements on 26 November 2018 and 18 March 2019, the Company announces that its ownership of the enlarged PDS Biotechnology Corporation ("PDS"), trading on Nasdaq under the ticker PDSB, on a fully-diluted basis is 8.15%, which at the listing price on 18 March 2019 of $10 values NetScientific's holding in PDS at £4,081,451*. It is the Company's intention to hold the shares and to make a decision on its position in due course.
*Using a US:GBP exchange rate of 1.33
# # #
For more information, please contact:
NetScientific François R. Martelet, M.D., CEO Ian Postlethwaite, CFO
| Tel: +44 (0)20 3514 1800 |
WH Ireland Limited (NOMAD, Financial Adviser and Broker) Chris Fielding / Jessica Cave
| Tel: +44 (0)20 7220 1666
|
Consilium Strategic Communications Mary-Jane Elliott / Chris Welsh / Laura Thornton NetScientific@consilium-comms.com | Tel: +44 (0)20 3709 5700
|
About NetScientific
NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.
For more information, please visit the website at http://www.NetScientific.net